The company exhibits a deeply negative operating margin of -59.2% as of 2026Q1, reflecting a business model where R&D costs consistently exceed $34 million per quarter.
| Sales/Revenue | 4.03M | 4.63M | 2.98M | 0 | 0 | 0 | 5.21M | 0 |
| Revenue Growth % | 4.89% | 55.28% | - | - | - | -100% | - | - |
| Cost of Goods Sold | 47.71M | 7.32M | 0 | 0 | 0 | 0 | 2.98M | 2.76M |
| COGS % of Revenue | - | 158.05% | - | - | - | - | 57.2% | - |
| Gross Profit | -43.68M | -2.69M | 2.98M | 0 | 0 | 0 | 2.23M | -2.76M |
| Gross Margin % | -1082.7% | -58.05% | 100% | - | - | - | 42.8% | - |
| Gross Profit Growth % | - | -190.14% | - | - | - | -100% | 180.8% | - |
| Operating Expenses | 162.94M | 205.66M | 205.45M | 204.79M | 116.54M | 84.47M | 3.16M | 2.17M |
| OpEx % of Revenue | - | 4440% | 6887.36% | - | - | - | 60.69% | - |
| Selling, General & Admin | 56.47M | 52.35M | 50.16M | 43.39M | 29.82M | 13.92M | 3.16M | 1.25M |
| SG&A % of Revenue | - | 1130.1% | 1681.56% | - | - | - | 60.69% | - |
| Research & Development | 154.18M | 160.64M | 155.29M | 147.91M | 86.72M | 70.55M | 2.98M | 920K |
| R&D % of Revenue | - | 3467.96% | 5205.8% | - | - | - | 57.2% | - |
| Other Operating Expenses | -3M | -7.32M | 0 | 13.5M | 0 | 0 | -2.98M | 0 |
| Operating Income | -206.61M | -208.35M | -202.47M | -204.79M | -116.54M | -84.47M | -932K | -2.17M |
| Operating Margin % | -5121.77% | -4498.06% | -6787.36% | - | - | - | -17.89% | - |
| Operating Income Growth % | - | -2.91% | 1.14% | -75.72% | -37.96% | -8963.73% | 57.09% | - |
| EBITDA | -199.13M | -202.97M | -196.34M | -200.14M | -114.32M | -83.91M | -889K | 4.34M |
| EBITDA Margin % | -4936.42% | -4381.82% | -6581.93% | - | - | - | -17.06% | - |
| EBITDA Growth % | 0.43% | -3.38% | 1.9% | -75.07% | -36.25% | -9338.25% | -120.47% | - |
| D&A (Non-Cash Add-back) | 7.48M | 5.38M | 6.13M | 4.65M | 2.22M | 568K | 43K | 6.52M |
| EBIT | -203.22M | -201.14M | -202.47M | -191.29M | -116.54M | -84.47M | -932K | -2.52M |
| Net Interest Income | 4.98M | 4.15M | 3.52M | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 4.98M | 4.15M | 3.52M | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 8.24M | 7.21M | 6.58M | 6.38M | -6.22M | -81.38M | -611K | 0 |
| Pretax Income | -198.37M | -201.14M | -195.88M | -198.41M | -122.77M | -165.85M | -1.54M | -2.52M |
| Pretax Margin % | -4917.55% | -4342.44% | -6566.61% | - | - | - | -29.62% | - |
| Income Tax | 0 | 0 | 0 | -279K | -948K | -486K | 1.87M | 4K |
| Effective Tax Rate % | 0% | 0% | 0% | 0.14% | 0.77% | 0.29% | -121% | -0.16% |
| Net Income | -198.37M | -201.14M | -195.88M | -198.13M | -121.82M | -165.37M | -3.41M | -2.53M |
| Net Margin % | -4917.55% | -4342.44% | -6566.61% | - | - | - | -65.45% | - |
| Net Income Growth % | 1.8% | -2.69% | 1.14% | -62.64% | 26.33% | -4749.47% | -34.84% | - |
| Net Income (Continuing) | -198.37M | -201.14M | -195.88M | -198.13M | -121.82M | -165.37M | -3.41M | -2.53M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.12 | -1.35 | -1.65 | -2.18 | -1.46 | -1.92 | -0.05 | -0.03 |
| EPS Growth % | 23.47% | 18.26% | 24.17% | -49.09% | 24.04% | -3542.61% | -80.82% | - |
| EPS (Basic) | - | -1.35 | -1.65 | -2.18 | -1.46 | -1.92 | -0.05 | -0.03 |
| Diluted Shares Outstanding | 177.1M | 148.76M | 118.6M | 90.97M | 97.21M | 95.73M | 95.73M | 95.73M |
| Basic Shares Outstanding | 177.1M | 148.76M | 118.6M | 90.97M | 97.21M | 95.73M | 95.73M | 95.73M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Insufficient Cash Runway
According to recent financial disclosures, Prime Medicine's revenue remains highly erratic, with a 41.1% year-over-year decline in 2026Q1, underscoring the company's reliance on lumpy, non-recurring collaboration payments rather than a sustainable commercial product pipeline that could provide predictable, long-term top-line growth for the organization.
The revenue profile is entirely contingent on the timing of technical milestones within strategic partnerships, which makes trend analysis difficult. Investors should interpret these fluctuations as indicators of research progress rather than market adoption, as the company lacks any commercialized therapeutic products.
As reported in quarterly filings, Prime Medicine maintains a heavy R&D expenditure profile, with quarterly research costs consistently exceeding $34 million, which dwarfs the nominal revenue inflows and highlights the firm's status as a pre-commercial entity focused exclusively on platform development rather than operational efficiency.
The persistent R&D spend suggests that management is prioritizing the advancement of its prime editing platform over near-term cost containment. This structure implies that the company will continue to face significant operating losses until it can successfully transition its lead programs into later-stage clinical trials.
Based on the provided income statement data, Prime Medicine exhibits a deeply negative operating margin, reaching -59.2% in 2026Q1, which indicates that the company has yet to achieve any meaningful operating leverage as its fixed overhead costs continue to scale independently of its limited revenue.
The lack of scalability in the current operating model is typical for early-stage biotech firms, but it warrants caution regarding the company's long-term sustainability. Without a significant increase in collaboration revenue or a reduction in fixed expenses, the firm remains highly sensitive to external funding cycles.
Data from recent filings reveals a precarious cash position of approximately $63 million, which, when measured against the company's consistent quarterly operating losses, suggests that the firm may face a liquidity crunch in the near term without securing additional non-dilutive capital or new strategic partnerships.
Short-term solvency appears to be the primary risk factor, as the current burn rate leaves little room for operational delays or clinical setbacks. Investors should monitor the company's ability to extend its runway, as the current financial trajectory may necessitate dilutive equity financing in the coming quarters.
Quick answers to the most common questions about buying PRME stock.
For fiscal year 2025, Prime Medicine, Inc. (PRME) reported total revenue of $4.6M.
Prime Medicine, Inc. (PRME) reported a net loss of $201.1M for the fiscal year ending 2025.
Prime Medicine, Inc. (PRME) reported an operating income of $-208.3M, resulting in an operating profit margin of -4498.1%. This margin reflects the operational efficiency of the business before interest and taxes.
Prime Medicine, Inc. (PRME) generated $-2.7M in gross profit for the year, representing a gross profit margin of -58.1%. This demonstrates the company's core pricing power and production efficiency.